Bernard Bégaud

9.5k total citations · 3 hit papers
179 papers, 6.8k citations indexed

About

Bernard Bégaud is a scholar working on Pharmacology, Psychiatry and Mental health and Geriatrics and Gerontology. According to data from OpenAlex, Bernard Bégaud has authored 179 papers receiving a total of 6.8k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Pharmacology, 37 papers in Psychiatry and Mental health and 34 papers in Geriatrics and Gerontology. Recurrent topics in Bernard Bégaud's work include Pharmaceutical Practices and Patient Outcomes (33 papers), Pharmacovigilance and Adverse Drug Reactions (25 papers) and Schizophrenia research and treatment (19 papers). Bernard Bégaud is often cited by papers focused on Pharmaceutical Practices and Patient Outcomes (33 papers), Pharmacovigilance and Adverse Drug Reactions (25 papers) and Schizophrenia research and treatment (19 papers). Bernard Bégaud collaborates with scholars based in France, Canada and Belize. Bernard Bégaud's co-authors include Nicholas Moore, Hélène Verdoux, Alexandre Pariente, Gilles Hayem, S. Dejager, Éric Bruckert, Yola Moride, Marie Tournier, Sophie Billioti de Gage and Rajaa Lagnaoui and has published in prestigious journals such as New England Journal of Medicine, Blood and PLoS ONE.

In The Last Decade

Bernard Bégaud

175 papers receiving 6.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mild to Moderate Muscular Symptoms with High-Dosage Statin Therapy in Hyperlipidemic Patients —The PRIMO Study

2005 926 citations Bernard Bégaud et al. Cardiovascular Drugs and Therapy profile →
Appetite-Suppressant Drugs and the Risk of Primary Pulmonary Hypertension

1996 813 citations Lucien Abenhaim, Yola Moride et al. profile →
Benzodiazepine use and risk of Alzheimer's disease: case-control study

2014 380 citations Yola Moride, Hélène Verdoux et al. profile →

Peers

Countries citing papers authored by Bernard Bégaud

Since Specialization

Citations

This map shows the geographic impact of Bernard Bégaud's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bernard Bégaud with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bernard Bégaud more than expected).

Fields of papers citing papers by Bernard Bégaud

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bernard Bégaud. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bernard Bégaud. The network helps show where Bernard Bégaud may publish in the future.

Co-authorship network of co-authors of Bernard Bégaud

This figure shows the co-authorship network connecting the top 25 collaborators of Bernard Bégaud. A scholar is included among the top collaborators of Bernard Bégaud based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bernard Bégaud. Bernard Bégaud is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Trajectories of Benzodiazepine Use among Older Adults from a Concordance-with-Guidelines Perspective: A Nationwide Cohort Study 2023 ·Drugs & Aging ·Sandy Maumus‐Robert, (unknown), Marie Tournier, Bernard Bégaud, Alexandre Pariente	3
2	Neurocognitive Disorders Associated with PCSK9 Inhibitors: a Pharmacovigilance Disproportionality Analysis 2021 ·Cardiovascular Drugs and Therapy ·Amandine Gouverneur, Paola Sanchez-Peña, G. Veyrac, Joe‐Elie Salem, Bernard Bégaud, Julien Bezin	7
3	Overview of French databases available for studying anticancer drugs in real‐life setting 2020 ·Fundamental and Clinical Pharmacology ·(unknown), Pernelle Noïze, Amandine Gouverneur, Driss Berdaï, Bernard Bégaud, L. Lévy-Bachelot, Mathiéu Molimard	8
4	Conventional mood stabilizers and/or second-generation antipsychotic drugs in bipolar disorders: A population-based comparison of risk of treatment failure 2019 ·Journal of Affective Disorders ·(unknown), Anke Neumann, Élodie Pambrun, Alain Weill, (unknown), François Alla, Bernard Bégaud, Géric Maura, Hélène Verdoux	12
5	Prevalence and prescription patterns of oral glucocorticoids in adults: a retrospective cross-sectional and cohort analysis in France 2017 ·BMJ Open ·Anne Bénard‐Laribière, Alexandre Pariente, Élodie Pambrun, Bernard Bégaud, L. Fardet, Pernelle Noïze	70
6	Fibrates and Risk of Cancer in Tissues with High PPAR-α Concentration: A Nested Case–Control Study 2014 ·Drug Safety ·Francesco Salvo, Fabienne Bazin, (unknown), (unknown), Philip Robinson, Nicholas Moore, Bernard Bégaud, Alexandre Pariente	4
7	Influence of the drug exposure definition on the assessment of the antipsychotic metabolic impact in patients initially treated with mood‐stabilizers 2012 ·British Journal of Clinical Pharmacology ·Marie Tournier, Bernard Bégaud, Audrey Cougnard‐Grégoire, (unknown), Jean Deligne, Claudine Blum‐Boisgard, Anne C. M. Thiébaut, Hélène Verdoux	6
8	Who seeks primary care for sleep, anxiety and depressive disorders from physicians prescribing homeopathic and other complementary medicine? Results from the EPI3 population survey 2012 ·BMJ Open ·Lamiae Grimaldi‐Bensouda, Pierre Engel, Jacques Massol, Didier Guillemot, Bernard Avouac, Gérard Duru, France Lert, (unknown), Michel Rossignol, Frédéric Rouillon, Lucien Abenhaim, Bernard Bégaud, (unknown)	16
9	Impact of Prescriber Nonresponse on Patient Representativeness 2008 ·Epidemiology ·Annie Fourrier‐Réglat, C. Droz‐Perroteau, Jacques Bénichou, F. Depont, M Amouretti, Bernard Bégaud, Yola Moride, Patrick Blin, Nicholas Moore	19
10	Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia 2006 ·Blood ·Stéphane Picard, Karine Titier, Gabriel Étienne, (unknown), Dominique Ducint, Marie‐Agnès Bernard, R. Lassalle, Gérald Marit, Josy Reiffers, Bernard Bégaud, Nicholas Moore, Mathiéu Molimard, François‐Xavier Mahon	468
11	Agreement of expert judgment in causality assessment of adverse drug reactions 2005 ·European Journal of Clinical Pharmacology ·Yannick Arimone, Bernard Bégaud, Ghada Miremont‐Salamé, Annie Fourrier‐Réglat, Nicholas Moore, Mathiéu Molimard, Françoise Haramburu	77
12	Hepatitis B Vaccination and First Central Nervous System Demyelinating Event: A Case-Control Study 2002 ·Neuroepidemiology ·Emmanuel Touzé, A Fourrier, (unknown), (unknown), (unknown), Bernard Bégaud, Annick Alpérovitch	73
13	Incidence et prévalence des effets indésirables des médicaments. 2000 ·La Presse Médicale ·Françoise Haramburu, (unknown), Jean‐Louis Imbs, Jean‐Pierre Blayac, Bernard Bégaud	4
14	Adverse drug reactions in a department of systemic diseases-oriented internal medicine: prevalence, incidence, direct costs and avoidability 2000 ·European Journal of Clinical Pharmacology ·Rajaa Lagnaoui, Nicholas Moore, (unknown), M. Longy‐Boursier, Bernard Bégaud	142
15	Long- and short-acting beta2 adrenoceptor agonists: interactions in human contracted bronchi 1998 ·European Respiratory Journal ·Mathiéu Molimard, Emmanuel Naline, (unknown), Vincent Gros, Bernard Bégaud, Charles Advenier	46
16	Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX- inhibiting Therapies (SELECT) trial in osteoarthritis 1998 ·Lara D. Veeken ·J. Dequeker, Christopher J. Hawkey, André Kahan, Klaus Steinbrück, C. Alegre, E. Baumelou, Bernard Bégaud, H Isomäki, Geoffrey Littlejohn, James Mau, S Papazoglou	169
17	Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment [published erratum appears in Br J Rheumatol 1998 Oct;37(10):1142] 1998 ·Lara D. Veeken ·C J Hawkey, André Kahan, Klaus Steinbrück, C. Alegre, E. Baumelou, Bernard Bégaud, J. Dequeker, H Isomäki, Geoffrey Littlejohn, James Mau, S Papazoglou	203
18	Appetite-suppressant drugs and the risk of primary pulmonary hypertension 1997 ·Pneumologie ·Lucien Abenhaim, Yola Moride, F Brénot, Stuart Rich, (unknown), Xavier Kurz, T W Higenbottam, Caroline Oakley, E.F.M. Wouters, Michel Aubier, G. Simonneau, Bernard Bégaud	7
19	Imputabilité des effets indésirables des médicaments. 1982 ·La Nouvelle presse médicale ·(unknown), Bernard Bégaud	24
20	Imputabilité des effets indésirables des médicaments. Etude de 194 observations. 1978 ·Therapies ·Bernard Bégaud, (unknown), H Albín, (unknown)	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact